Abiopharma

🔍 Feuchtwang Ilan (Executive)

Company: Cytek Biosciences, Inc. (CTKB)

Report Date: 2026-08-10

Detailed Transactions and Holdings:

• Acquired 241,416 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 241,416.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 127,118 shares of Employee Stock Option (right to buy) at $4.66 per share (Derivative)
  Date: 2026-08-10 | Code: A | Expires: 2036-08-09 | equity_swap_involved: 0 | shares_owned_after: 127,118.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
• F2: The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on August 18, 2027; 3/48 of the RSUs vesting on November 18, 2027 and each November 18 thereafter; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; and 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan"))).
• F3: The shares subject to the option shall vest over 4 years with 25% vesting on August 10, 2027 and 1/48 of the shares vesting each month thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the 2021 Plan)).